Valencian Health Authority Awards 8.7 Billion Euro Biosimilars Framework Agreement to Eight Pharmaceutical Suppliers

Standfirst

A group of eight pharmaceutical suppliers has been appointed to a major framework agreement for the supply of biological medicines and biosimilars to public health centers in the Valencian region of Spain. The contract, managed by the General Directorate of Economic Management, Contracting and Infrastructure of the Ministry of Health, carries a maximum estimated framework value of approximately 8.73 billion euros across all lots.

This procurement highlights the Spanish public sector ongoing commitment to healthcare sustainability and the strategic adoption of cost effective biosimilar alternatives. The award follows a competitive open procedure that balanced clinical quality with financial efficiency, ensuring reliable access to advanced treatments for regional patients.

Introduction

The modernization of public healthcare procurement represents a critical priority for regional governments across Europe. In Spain, the Valencian health authority has initiated a large scale procurement strategy to supply biological medicines and biosimilars to various public health centers. This specific tender result focuses on the acquisition of essential treatments, including immunosuppressive agents, antineoplastic agents, and other specialized biological medications required for chronic and complex disease management.

By utilizing a centralized framework agreement model, the contracting authority leverages collective buying power to secure favorable terms and standardized product specifications. The agreement permits both direct awards and reopened competition, providing flexibility to meet the diverse clinical needs of different hospitals while maintaining strict control over public expenditure. This approach ensures that taxpayer funds are deployed efficiently while adhering to European public procurement regulations.

Why This Contract Matters

This framework agreement is vital for ensuring that public health services have reliable and affordable access to advanced biological treatments. The inclusion of environmental criteria aligns the procurement with broader sustainability goals, pushing the pharmaceutical market toward greener supply chain practices. For the pharmaceutical industry, securing a position on this official Tenders Portal list guarantees access to a massive and stable customer base. The high maximum value indicates significant future revenue potential, although actual spending will depend on the specific call off orders issued by individual health centers.

Contract Timeline

The procurement process culminated in the formal selection of the winning suppliers on June 4, 2026. Following the mandatory administrative and standstill periods, the framework contracts were officially concluded on August 28, 2026. The contract awards notice was subsequently published in the Official Journal of the European Union on September 8, 2026. This timeline reflects a standard and transparent execution of public procurement regulations in the Spanish healthcare sector.

Contract Overview

The procurement is structured as a framework agreement that is partly without reopening and partly with reopening of competition. This means that the terms, including pricing, were established during the initial tender evaluation, and individual purchase orders will be issued based on these pre agreed conditions or through mini competitions. The maximum estimated value of the framework agreements across all lots is set at 8,735,686,152.30 euros. Eight distinct suppliers were selected across various therapeutic lots, ensuring a wide array of product options for healthcare providers.

Key Contract Details

Project Scope

The scope of this contract covers the environmentally friendly supply of biological medicines with biosimilars intended for public health centers. These products are classified under primary CPV codes for immunosuppressive agents, antineoplastic agents, and medicinal products for obstructive airway diseases. The suppliers are responsible for ensuring the timely delivery of these critical items to regional healthcare facilities in accordance with strict pharmaceutical storage and handling regulations. The agreement also mandates a focus on pollution prevention and climate change mitigation throughout the supply chain.

About the Contracting Authority

The General Directorate of Economic Management, Contracting and Infrastructure of the Ministry of Health is the primary contracting authority. It is a regional public authority responsible for managing healthcare procurement and infrastructure within the Valencian Community, Spain.

About the Organisations Involved

Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad is the primary contracting authority and buyer. It manages regional healthcare services and drives the procurement of essential medical supplies for public hospitals.

AMGEN, S.A. is a successful bidder and a large economic operator. The company secured the contract for LOT 0012, supplying Adalimumab 20mg pre filled syringes or pens.

KERN PHARMA, S.L. is a successful bidder and a large economic operator. It won multiple lots, including LOT 0002, LOT 0011, LOT 0013, and LOT 0017, demonstrating strong capacity in immunosuppressive agents.

Celltrion Farmaceutica España SL is a successful bidder and a micro, small, or medium enterprise. It secured six lots, including LOT 0007, LOT 0008, LOT 0010, LOT 0015, LOT 0016, and LOT 0018, highlighting its significant role in the biosimilars market.

SAMSUNG BIOEPIS NL BV is a successful bidder and a large economic operator based in the Netherlands. It was awarded LOT 0019 for the supply of Eculizumab.

ACCORD HEALTHCARE, SLU is a successful bidder and a large economic operator. The company won LOT 0005 and LOT 0022, focusing on antineoplastic and immunomodulating agents.

GEDEON RICHTER IBERICA SAU is a successful bidder and a large economic operator. It secured LOT 0023 for the supply of Folitropina alfa.

Sandoz Farmaceutica is a successful bidder and a large economic operator. It was awarded LOT 0003 and LOT 0004, supplying Infliximab and Natalizumab.

ORION PHARMA S.L. is a successful bidder and a micro, small, or medium enterprise. It won LOT 0006 for the supply of Ranibizumab.

Tribunal Administrativo Central de Recurso Contractuales is the review organisation. This Central Administrative Court of Contractual Appeals handles any legal challenges or disputes related to the procurement process.

Procurement Analysis

The open procedure attracted multiple bids across the various lots, demonstrating healthy competition in the Spanish biosimilars market. The award criteria were split between quality and price, with quality carrying a weight of 50 or 60 points and price carrying 40 or 50 points depending on the specific lot. This balanced evaluation method indicates that the technical and clinical specifications in the bidding documents were stringent, requiring suppliers to prove both clinical efficacy and financial competitiveness. Consequently, the competition focused on delivering optimal value without compromising patient safety or treatment standards.

Additional Procurement Facts

The procurement is not covered by the Government Procurement Agreement, reflecting its status as a domestic regional contract governed primarily by Spanish national legislation and EU Directive 2014/24/EU. The project is not financed with European Union funds, relying instead on the regional healthcare budget. The framework agreement structure allows for both direct awards and reopened competition, providing flexibility for future purchasing decisions.

Market & Industry Perspective

The Spanish public pharmaceutical market is highly competitive, with major international manufacturers and local distributors vying for centralized contracts. The presence of eight winners across multiple lots indicates that the contracting authority values supplier diversity to mitigate the risk of supply chain disruptions. This approach ensures that if one manufacturer faces production delays, alternative approved biosimilar products remain immediately available to healthcare providers. The emphasis on environmental criteria also signals a broader industry shift toward sustainable pharmaceutical logistics.

Economic Significance

A maximum framework value of approximately 8.73 billion euros represents a substantial allocation of public healthcare spending. This investment supports the domestic and regional distribution networks of major pharmaceutical companies, ensuring the continued availability of critical medical supplies. By securing these prices in advance, the region achieves significant budgetary predictability and protects against market volatility in the pricing of biological medicines.

Future Procurement Opportunities

Suppliers who were not successful should monitor the official Tenders Portal for upcoming framework renewals or new lots covering different therapeutic areas. As clinical guidelines evolve, public institutions will continuously generate new tenders opportunities for medication refreshes. Stakeholders should also track the Latest Active Tenders Procurement notices to anticipate upcoming supply projects in the broader Spanish healthcare sector. The dynamic nature of public procurement means that new Live Notices for Tenders will emerge as regional authorities update their clinical requirements.

Opportunities for Suppliers

While the primary framework positions have been awarded, specialized logistics providers and cold chain transport companies can find valuable subcontracting opportunities with the primary winners. Additionally, manufacturers of specific generic alternatives may explore partnerships with the appointed distributors to expand their market reach within the public sector.

What Businesses Should Watch

Industry observers should monitor the activation rate of this framework agreement to gauge actual public sector demand for these specific pharmaceutical products. The balance between direct awards and reopened competitions will reveal how contracting entities value flexibility versus price competition in subsequent phases. Stakeholders should also review Live Notices for Tenders to anticipate upcoming infrastructure projects and supply chain modernizations in the region. Any shifts in clinical guidelines regarding biological treatments will directly influence future RFPs and RFQs in this market.

SpainTenders.com Procurement Intelligence

This contract represents a clear trend in European public procurement toward the strategic adoption of biosimilars to ensure long term healthcare sustainability. By appointing eight different providers across various therapeutic categories, the Valencian health authority mitigates the risk of stock shortages and manufacturer delays that have historically plagued public healthcare systems. This strategy prioritizes operational continuity and clinical flexibility over the traditional model of selecting a single exclusive supplier for all biological medicines.

Strategically, this award is important because it demonstrates a balanced evaluation approach in high value medical tenders. By assigning significant weight to both quality and price, the buyer effectively pre qualified compliant bidders based on their ability to meet stringent clinical and regulatory baselines while remaining cost competitive. Suppliers can learn that meeting these technical minimums is now the primary hurdle, rather than competing solely on marginal price differences during the initial framework establishment.

To position themselves for future contracts, relevant suppliers must invest in supply chain transparency and ensure their product catalogs align with national clinical guidelines and environmental standards. Future contracts in this market are likely to feature even stricter supply chain security mandates alongside price competition. Companies that proactively develop resilient distribution networks and can guarantee uninterrupted delivery will hold a distinct advantage when responding to future public procurement solicitations.

Supplier Takeaways

• Multi supplier framework agreements are increasingly used to guarantee supply chain resilience in public healthcare procurement.
• Meeting strict clinical and regulatory minimums is a primary gateway for winning government pharmaceutical contracts.
• The real competition often shifts to the call off phase, requiring suppliers to maintain agile response capabilities for reopened competitions.
• Specialized logistics and cold chain providers can find valuable subcontracting opportunities with primary framework winners.

Key Takeaways

• Eight suppliers were awarded positions on a framework agreement for biological medicines and biosimilars.
• The maximum estimated value of the framework agreements is approximately 8.73 billion euros.
• The award criteria balanced quality and price, reflecting a mature market for specialized hospital pharmaceuticals.
• The framework operates with both direct awards and reopened competition, ensuring flexibility for healthcare providers.
• Environmental sustainability criteria were integrated into the procurement to promote greener supply chains.

Conclusion

This framework agreement secures a reliable and diversified supply of critical biological medicines for the Valencian public health system. The multi supplier award structure ensures competitive tension and operational resilience for the duration of the contract. As the region continues to modernize its healthcare delivery, this procurement model will likely serve as a blueprint for future pharmaceutical acquisitions.

Source: Tenders Electronic Daily (TED), Contract Award Notice 617533-2026, Official Journal of the European Union, published on 08/09/2026.